At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 439 enrolled
Drug / intervention
desvenlafaxine succinate sustained-release +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder
In Brief
A Phase 4 clinical trial evaluating desvenlafaxine succinate sustained-release and placebo for Major Depressive Disorder. Completed, enrolled 439 participants across 44 sites.
Detailed Summary
A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedMay 12, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.1 years ago
Interventions
desvenlafaxine succinate sustained-releasedrug
50-mg DVS SR tablets taken orally once daily.
placebodrug
Placebo tablets taken orally once daily.